Mustang Bio, Inc.
METHODS OF TREATMENT USING DECITABINE AND A CD123-TARGETED THERAPY

Abstract:

The present disclosure relates generally to methods treatment of hematological cancers, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), or Myelodysplastic Syndrome (MDS), comprising a combination of decitabine and a CD123-targeted therapy. In particular, the disclosed methods involve pretreatment of a patient with decitabine prior to administration of a CD123-targeted therapy.